CNS Response to Osimertinib Versus Standard Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.
PubWeight™: 3.34‹?›
| Rank: Top 1%
Published in J Clin Oncol on August 28, 2018
Authors
Thanyanan Reungwetwattana1, Kazuhiko Nakagawa1, Byoung Chul Cho1, Manuel Cobo1, Eun Kyung Cho1, Alessandro Bertolini1, Sabine Bohnet1, Caicun Zhou1, Ki Hyeong Lee1, Naoyuki Nogami1, Isamu Okamoto1, Natasha Leighl1, Rachel Hodge1, Astrid McKeown1, Andrew P Brown1, Yuri Rukazenkov1, Suresh S Ramalingam1, Johan Vansteenkiste1
Author Affiliations
1: Thanyanan Reungwetwattana, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand; Kazuhiko Nakagawa, Kindai University School of Medicine, Osaka; Naoyuki Nogami, National Hospital Organization Shikoku Cancer Center, Matsuyama; Isamu Okamoto, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan; Byoung Chul Cho, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul; Eun Kyung Cho, Gachon University Gil Medical Center, Incheon; Ki Hyeong Lee, Chungbuk National University Hospital, Cheong-ju, Republic of Korea; Manuel Cobo, Institute of Biomedical Research in Málaga, Málaga University Hospital Regional, Málaga, Spain; Alessandro Bertolini, Hospital of Sondrio, Sondrio, Italy; Sabine Bohnet, Universitätsklinik Schleswig-Holstein, Lübeck, Germany; Caicun Zhou, Pulmonary Hospital of Tongji University, Shanghai, People's Republic of China; Natasha Leighl, Princess Margaret Cancer Centre, Toronto, Ontario, Canada; Rachel Hodge, Astrid McKeown, Andrew P. Brown, and Yuri Rukazenkov, AstraZeneca, Cambridge, United Kingdom; Suresh S. Ramalingam, Winship Cancer Institute, Emory University, Atlanta, GA; and Johan Vansteenkiste, University Hospital, Katholieke Universiteit Leuven, Leuven, Belgium.